Immuneering Corporation is a biotechnology business based in the US. Immuneering Corporation shares (IMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Immuneering Corporation employs 36 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $12.32 |
|---|---|
| 52-week range | $11.03 - $33.99 |
| 50-day moving average | $21.07 |
| 200-day moving average | $24.36 |
| Wall St. target price | $39.25 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.44 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.32 from 2022-01-19
| 1 week (2022-01-14) | -5.23% |
|---|---|
| 1 month (2021-12-21) | -45.22% |
| 3 months (2021-10-21) | -52.83% |
| 6 months (2021-07-17) | N/A |
| 1 year (2021-01-17) | N/A |
|---|---|
| 2 years (2020-01-17) | N/A |
| 3 years (2019-01-17) | N/A |
| 5 years (2017-01-17) | N/A |
| Revenue TTM | $2.6 million |
|---|---|
| Gross profit TTM | $1 million |
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $6.10 |
| Market capitalisation | $324.3 million |
TTM: trailing 12 months
We're not expecting Immuneering Corporation to pay a dividend over the next 12 months.
Immuneering Corporation is a biopharmaceutical company with a pipeline focusing on improving patient outcomes across a spectrum of oncologic and neurologic diseases by applying its bioinformatics to every stage of the drug development process. It provides bioinformatics and generates insights into drug mechanisms of action and patient treatment responses. The company was incorporated in 2008 and is based in Cambridge, Massachusetts. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.